US Stock MarketDetailed Quotes
BEAM Beam Therapeutics
- 26.650
- +1.600+6.39%
Close Nov 25 16:00 ET
- 26.650
- 0.0000.00%
Post 16:47 ET
2.21BMarket Cap-16867P/E (TTM)
26.900High25.590Low1.22MVolume25.940Open25.050Pre Close32.18MTurnover1.77%Turnover RatioLossP/E (Static)82.81MShares49.50052wk High2.79P/B1.83BFloat Cap20.84052wk Low--Dividend TTM68.63MShs Float138.522Historical High--Div YieldTTM5.23%Amplitude13.000Historical Low26.434Avg Price1Lot Size
About Beam Therapeutics Company
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Company Profile
SymbolBEAM
Company NameBeam Therapeutics
Listing DateFeb 6, 2020
Issue Price17.00
Founded2017
CEOMr. John Evans
MarketNASDAQ
Employees436
Fiscal Year Ends12-31
Address238 Main Street,9th floor
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142-1016
Phone1-857-327-8775
Websitehttp://www.beamtx.com
Company Executives
- Name
- Position
- Salary
- John Evans
- Chief Executive Officer, Principal Financial and Accounting Officer and Director
- 6.28M
- Dr. Amy Simon, M.D.
- Chief Medical Officer
- 2.55M
- Dr. Christine Bellon, PhD
- Chief Legal Officer and Secretary
- 2.28M
- Dr. Giuseppe Ciaramella, PhD
- President
- 2.79M
- Dr. Carole Ho, M.D.
- Independent Director
- 442.72K
- Graham K. Cooper
- Independent Director
- 450.22K
- Dr. Mark C. Fishman, M.D.
- Lead Independent Director
- 465.22K
- Christi Shaw
- Independent Director
- 772.68K
- Dr. John M. Maraganore,PhD
- Independent Director
- 435.22K
- Kathleen E. Walsh
- Independent Director
- 447.72K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
